SCYX - SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference January 25 – 27 in Milan Italy | Benzinga
JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 for the treatment of mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis (AAAM) Conference in Milan, Italy from January 25 – 27, 2024.
| Poster Presentation: |
| Title: |
| SCY-247, a novel second-generation IV/oral triterpenoid antifungal, is efficacious in the neutropenic mouse model of pulmonary mucormycosis |
| Presenting author: |
| Dr. Ashraf Ibrahim, PhD, FAAM, FECCM (Professor of Medicine, Division of Infectious Disease, David Geffen School of Medicine UCLA) |
In this preclinical study, SCY-247 demonstrated in vivo efficacy equivalent to currently used antifungals in treating a Mucorales pulmonary infection in immunosuppressed mice. Notably, the combination of SCY-247 with liposomal amphotericin B resulted in a significant survival improvement when compared to monotherapy.
"The results from this preclinical study are very encouraging and illustrate the significant potential for this novel fungerp ...